Journal article
Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study
R Deng, L Gibiansky, T Lu, X Li, D Lu, C Li, S Girish, J Wang, M Boyer, N Shankar, K Humphrey, KJ Freise, AH Salem, JF Seymour, AP Kater, D Miles
Leukemia and Lymphoma | TAYLOR & FRANCIS LTD | Published : 2020
Abstract
Exposure–response relationships from a phase 1b (M13-365) and phase 3 (MURANO) study were investigated to assess benefit/risk of venetoclax 400 mg daily plus rituximab in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dose intensities were summarized by tertiles of predicted venetoclax steady-state average concentrations based on nominal venetoclax dose (CmeanSS,nominal) for tolerability; exposure–safety analyses used logistic regression. Exposure–progression-free survival (PFS) relationships were assessed using MURANO data, with CmeanSS,nominal as a grouping factor. Covariates were demographics, geographic region, study, baseline disease characteristics, ECOG performance stat..
View full abstractGrants
Funding Acknowledgements
The authors thank the patients, enrolling physicians, site staff, and venetoclax study teams. The authors also thank Dr Mehrdad Mobasher for his valuable contributions to the manuscript. Third-party medical writing assistance was provided by Christopher Dunn and Andrew Sutton of GardinerCaldwell Communications, and was funded by F. Hoffmann - La Roche Ltd.